New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
10:36 EDTAZN, URBN, BPL, FST, TJXHigh option volume stocks: TJX BPL AZN FST URBN
News For TJX;BPL;AZN;FST;URBN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 17, 2014
06:43 EDTAZNAstraZeneca, Pfizer deal seen less likely after Merck transaction, Reuters says
Subscribe for More Information
November 16, 2014
13:36 EDTAZNAstraZeneca presents data from studies of lesinurad combined with allopurinol
Subscribe for More Information
November 14, 2014
14:53 EDTAZNCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
10:00 EDTURBN, TJXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:15 EDTTJXTJX downgraded to Sell at Canaccord
As reported previously, Canaccord downgraded TJX to Sell from Hold citing expectations for a deceleration of growth over the long term. The firm raised its price target on the stock, however, to $58 from $54.
07:14 EDTAZNAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
06:36 EDTTJXTJX downgraded to Sell from Hold at Canaccord
Subscribe for More Information
05:45 EDTURBNUrban Outfitters downgraded to Neutral from Buy at Mizuho
Subscribe for More Information
November 13, 2014
11:49 EDTTJXTJX November volatility increases into Q3 and outlook
Subscribe for More Information
10:19 EDTURBNUrban Outfitters volatility up into Q3 and holiday sales outlook
Subscribe for More Information
07:16 EDTAZNBIT Congress to hold a conference
Subscribe for More Information
07:03 EDTAZNAstraZeneca initiates development program for Brilinta reversal agent
Subscribe for More Information
05:34 EDTAZNAstraZeneca, Isis Pharmaceuticals to co-develop oligonucleotide delivery methods
Subscribe for More Information
November 12, 2014
11:17 EDTAZNLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
07:35 EDTAZNAdvaxis submits IND application for ADXS-HPV Phase 1/2 study, MEDI4736
Advaxis (ADXS) announced that the company has submitted an Investigational New Drug application, or IND, to the FDA to conduct a Phase 1/2 study of ADXS-HPV alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. This follows the press release issued in July announcing the clinical trial collaboration between Advaxis and MedImmune, the global biologics research and development arm of AstraZeneca (AZN).
November 11, 2014
16:05 EDTAZNAmgen, AstraZeneca say Phase 3 brodalumab study met endpoints
Subscribe for More Information
15:43 EDTAZNLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
November 10, 2014
16:20 EDTFSTForest Oil reports Q3 EPS 0.0c, consensus (5c)
Reports Q3 revenue $62.1M, consensus $67.31M.
15:26 EDTFSTNotable companies reporting after market close
Subscribe for More Information
05:48 EDTURBNU.S. Retail Softlines industry cut to Negative at Barclays
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use